{"success":true,"data":{"pressRelease":{"id":"141835","rtpr_id":"nGNX8q0w99-20260911","ticker":"ALCLS","exchange":"Euronext Paris","all_tickers":["ALCLS"],"title":"Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update","author":"Globe Newswire","published_at":"2026-09-11T20:29:59.904Z","article_body":"NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis\n(https://www.globenewswire.com/Tracker?data=Oe52355Da9BuAmTsTnbNRwDT1TKv94F3leCm_zegrj3FSH5mmmINrWlD1gbBnjeOE2h3o50vCHCy-9pXmhFORQ==)\n(the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage\nbiotechnology company using its pioneering gene editing platform to develop\nlife-saving cell and gene therapies, today announced that it will host a\nconference call and webcast on Monday, September 14, 2026 to provide a\nbusiness update.\n\nConference Call and Webcast Details:\n\nSeptember 14, 2026\n* English-language at 8:00 a.m. ET. / 2:00 p.m. CET\nWebcast link:\nhttps://viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480\nPhone number: +1 (800) 717 1738 or +1 (646) 307 1865\nFrance Toll Free: +33 (800) 945 120\n* French-language at 9:00 a.m. ET. / 3:00 p.m. CET\nWebcast link:\nhttps://viavid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca\nPhone number: +1 (800) 717 1738 or +1 (646) 307 1865\nFrance Toll Free: +33 (800) 945 120\n\nA replay will be available on the Company’s website\n(https://www.globenewswire.com/Tracker?data=KXA_bJ0bdLsaVA5zFNGZFCDuqWygq-nEBfGwztRHVUMBcHApSV5LiQMSzRV8-gHknZtLKMCllU5F8iwhnDXie9EAE0sdtLgTkIvkkvynyf5rFzY8VnXnp5jWCGXeQw5sqcmNVqXrl7ej_iS2fzyULg==)\nfollowing the event.  \n\nAbout Cellectis     \nCellectis is a clinical-stage biotechnology company using its pioneering\ngene-editing platform to develop life-saving cell and gene therapies. The\ncompany utilizes an allogeneic approach for CAR T immunotherapies in\noncology, pioneering the concept of off-the-shelf and ready-to-use\ngene-edited CAR T-cells to treat cancer patients, and a platform to develop\ngene therapies in other therapeutic indications. With its in-house\nmanufacturing capabilities, Cellectis is one of the few end-to-end gene\nediting companies that controls the cell and gene therapy value chain from\nstart to finish. Cellectis’ headquarters are in Paris, France, with\nlocations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq\nGlobal Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find\nout more, visit www.cellectis.com and follow Cellectis on LinkedIn\n(https://www.globenewswire.com/Tracker?data=CqzXDuQK-ohbfht7mGQC1im5Hk_lJ6geNuvbvV5Sna6w96WbJ1kQO7M3OvlC3l0ZSgFXugOBTmncppHWl8klQ7nqFzgfWT3D37NFrJAnB6R7xzVaAJQyUM_JtMqYqM9T)\nand X\n(https://www.globenewswire.com/Tracker?data=tw6zDfIFdH9fet-Q2zwdv48UL1YW8bmP17WrNrxlLwNKF2q_PgTZnTX_CgCaTCzFeeIJp_Di1ET_hkKAI1x1rw==).  \n\nFor further information on Cellectis, please\ncontact:         \n     \nMedia contacts:              \nPascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, \nPatricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,\nmedia@cellectis.com\nInvestor Relations contact:           \nArthur Stril, Chief Financial Officer & Chief Business\nOfficer, investors@cellectis.com\n\nAttachment\n* PRESS RELEASE_conference call_ENGLISH\n(https://ml.globenewswire.com/Resource/Download/0b5bb3dc-fd34-48a8-ab2a-a13f19bdaef7)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a84ce25b-a774-4635-9b79-d45241f5decc)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8q0w99-20260911","title":"Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update","author":"Globe Newswire","ticker":"ALCLS","created":"2026-09-11T20:29:59.904Z","tickers":["ALCLS"],"exchange":"Euronext Paris","article_body":"NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis\n(https://www.globenewswire.com/Tracker?data=Oe52355Da9BuAmTsTnbNRwDT1TKv94F3leCm_zegrj3FSH5mmmINrWlD1gbBnjeOE2h3o50vCHCy-9pXmhFORQ==)\n(the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage\nbiotechnology company using its pioneering gene editing platform to develop\nlife-saving cell and gene therapies, today announced that it will host a\nconference call and webcast on Monday, September 14, 2026 to provide a\nbusiness update.\n\nConference Call and Webcast Details:\n\nSeptember 14, 2026\n* English-language at 8:00 a.m. ET. / 2:00 p.m. CET\nWebcast link:\nhttps://viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480\nPhone number: +1 (800) 717 1738 or +1 (646) 307 1865\nFrance Toll Free: +33 (800) 945 120\n* French-language at 9:00 a.m. ET. / 3:00 p.m. CET\nWebcast link:\nhttps://viavid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca\nPhone number: +1 (800) 717 1738 or +1 (646) 307 1865\nFrance Toll Free: +33 (800) 945 120\n\nA replay will be available on the Company’s website\n(https://www.globenewswire.com/Tracker?data=KXA_bJ0bdLsaVA5zFNGZFCDuqWygq-nEBfGwztRHVUMBcHApSV5LiQMSzRV8-gHknZtLKMCllU5F8iwhnDXie9EAE0sdtLgTkIvkkvynyf5rFzY8VnXnp5jWCGXeQw5sqcmNVqXrl7ej_iS2fzyULg==)\nfollowing the event.  \n\nAbout Cellectis     \nCellectis is a clinical-stage biotechnology company using its pioneering\ngene-editing platform to develop life-saving cell and gene therapies. The\ncompany utilizes an allogeneic approach for CAR T immunotherapies in\noncology, pioneering the concept of off-the-shelf and ready-to-use\ngene-edited CAR T-cells to treat cancer patients, and a platform to develop\ngene therapies in other therapeutic indications. With its in-house\nmanufacturing capabilities, Cellectis is one of the few end-to-end gene\nediting companies that controls the cell and gene therapy value chain from\nstart to finish. Cellectis’ headquarters are in Paris, France, with\nlocations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq\nGlobal Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find\nout more, visit www.cellectis.com and follow Cellectis on LinkedIn\n(https://www.globenewswire.com/Tracker?data=CqzXDuQK-ohbfht7mGQC1im5Hk_lJ6geNuvbvV5Sna6w96WbJ1kQO7M3OvlC3l0ZSgFXugOBTmncppHWl8klQ7nqFzgfWT3D37NFrJAnB6R7xzVaAJQyUM_JtMqYqM9T)\nand X\n(https://www.globenewswire.com/Tracker?data=tw6zDfIFdH9fet-Q2zwdv48UL1YW8bmP17WrNrxlLwNKF2q_PgTZnTX_CgCaTCzFeeIJp_Di1ET_hkKAI1x1rw==).  \n\nFor further information on Cellectis, please\ncontact:         \n     \nMedia contacts:              \nPascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, \nPatricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,\nmedia@cellectis.com\nInvestor Relations contact:           \nArthur Stril, Chief Financial Officer & Chief Business\nOfficer, investors@cellectis.com\n\nAttachment\n* PRESS RELEASE_conference call_ENGLISH\n(https://ml.globenewswire.com/Resource/Download/0b5bb3dc-fd34-48a8-ab2a-a13f19bdaef7)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a84ce25b-a774-4635-9b79-d45241f5decc)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-11T20:29:59.947740201Z","server_sent_at_ms":1789158599947},"received_at":"2026-09-11T20:30:00.033Z","source_url":null},"analysis":{"id":"130673","press_release_id":"141835","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Business-update call scheduled with only weekend notice (announced Friday, Sept. 11 for a Monday, Sept. 14 call) — short-notice business updates can precede material announcements such as financing, pipeline, or leadership changes"],"eventType":"other","narrative":"Cellectis will host a business-update conference call and webcast on Monday, September 14, 2026, with an English-language session at 8:00 a.m. ET and a French-language session at 9:00 a.m. ET.\n\nThe release is a calendar notice only — dial-in numbers, webcast links, and replay availability on the company website — with no financial results, clinical data, or strategic news disclosed.\n\nThe Paris-headquartered, clinical-stage gene-editing biotech, which trades on Euronext Growth as ALCLS and on Nasdaq as CLLS, has pushed the substantive content to the call itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar notice only — monitor the September 14 call for the substantive pipeline and cash-runway update."},"keyFigures":{"customDimensions":{"call_date":"September 14, 2026","call_sessions":"English session 8:00 a.m. ET / French session 9:00 a.m. ET"}},"namedEntities":{"people":[{"name":"Pascalyne Wilson","role":"Director, Communications"},{"name":"Patricia Sosa Navarro","role":"Chief of Staff to the CEO"},{"name":"Arthur Stril","role":"Chief Financial Officer & Chief Business Officer"}],"products":[],"companies":[{"name":"Cellectis","ticker":"CLLS","relationship":"filer (issuer of the release; Euronext Growth ticker ALCLS, Nasdaq Global Market ticker CLLS)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine IR scheduling advisory announcing an upcoming business-update call; the release contains no financial results, clinical data, or strategic decisions, only call logistics and webcast links."},"tickerRelevance":{"others":[{"ticker":"CLLS","relevance":"same issuer — Nasdaq Global Market listing"}],"primary":"ALCLS"},"globalImportance":6,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech; foreign issuer (Euronext Growth primary listing for ALCLS)","eventGravity":"calendar-advisory, no new information","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Cellectis will host a business-update conference call and webcast on Monday, September 14, 2026, with an English-language session at 8:00 a.m. ET and a French-language session at 9:00 a.m. ET.\n\nThe release is a calendar notice only — dial-in numbers, webcast links, and replay availability on the company website — with no financial results, clinical data, or strategic news disclosed.\n\nThe Paris-headquartered, clinical-stage gene-editing biotech, which trades on Euronext Growth as ALCLS and on Nasdaq as CLLS, has pushed the substantive content to the call itself.","key_figures":{"customDimensions":{"call_date":"September 14, 2026","call_sessions":"English session 8:00 a.m. ET / French session 9:00 a.m. ET"}},"named_entities":{"people":[{"name":"Pascalyne Wilson","role":"Director, Communications"},{"name":"Patricia Sosa Navarro","role":"Chief of Staff to the CEO"},{"name":"Arthur Stril","role":"Chief Financial Officer & Chief Business Officer"}],"products":[],"companies":[{"name":"Cellectis","ticker":"CLLS","relationship":"filer (issuer of the release; Euronext Growth ticker ALCLS, Nasdaq Global Market ticker CLLS)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-11T20:30:33.238Z","global_importance":6,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap clinical-stage biotech; foreign issuer (Euronext Growth primary listing for ALCLS)","eventGravity":"calendar-advisory, no new information","issuerAuthored":true,"householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":33181,"modelName":"glm-5.3-flash"}}